Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.47 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.45 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.45 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192779 | 0.84 | NAE1 (0.61) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL17875179 | 0.84 | NAE1 (0.61) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL192337 | 0.82 | CA2 (0.49) | METTL3CA2PRMT5WDR77NAE1 | |
| SCHEMBL192440 | 0.82 | CA2 (0.49) | METTL3CA2PRMT5WDR77NAE1 | |
| SCHEMBL10186266 | 0.82 | RXFP1 (0.39) | CA2PRMT5WDR77NAE1GRK5 | |
| SCHEMBL13170761 | 0.81 | AHCY (0.54) | METTL3PRMT5WDR77 | |
| SCHEMBL10186262 | 0.81 | AHCY (0.52) | METTL3PRMT5WDR77 | |
| SCHEMBL13170714 | 0.80 | NAE1 (0.49) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL191900 | 0.80 | PRMT5 (0.51) | METTL3CA2PRMT5WDR77NAE1 | |
| SCHEMBL10186282 | 0.80 | METTL3 (0.47) | METTL3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | METTL3 4649/4885CA2 3826/4885PRMT5 870/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | METTL3 4649/4885CA2 3826/4885PRMT5 870/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | METTL3 4649/4885CA2 3826/4885PRMT5 870/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | METTL3 4649/4885CA2 3826/4885PRMT5 870/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | METTL3 4441/4885CA2 3434/4885PRMT5 822/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | METTL3 4649/4885CA2 3826/4885PRMT5 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.